Author: Rob

Stablepharma Ltd closed Series A funding round of $6.4m to progress the development of fridge-free vaccines and mRNA/LNP stabilisation technologies. Stablepharma Ltd, the Fridge-Free Vaccine Company closed their Series A funding round having secured a two-part £5.2m / $6.4m in total.  Lead investors are Hamilton Portfolio & Oval Investments, along with CrowdCube and backing of […]

We are delighted to announce that Johnny Sutton, founder and CEO of Oval Investments, will become a member of the Board of Stablepharma Ltd. Johnny joins the Board of the ‘Fridge-free Vaccine Company’, following Oval Investments’ major participation in the Series A fundraise, recently completed on 31st October 2022. https://stablepharma.com/team/johnny-sutton/ With extensive experience within Investment […]

Stablepharma Ltd, the Fridge-free Vaccine Company and BB-NCIPD Ltd (Bul Bio) are delighted to announce that we have signed a definitive agreement for the exclusive bulk supply and commercialisation of the Tetanus diphtheria vaccine, on September 20th, 2022. This agreement follows the head of terms signed in 2022 and consolidates the relationship between Stablepharma Ltd […]

Stablepharma and BB-NCIPD Ltd (Bul Bio) establish thermostability of StablevaX™-Td Vaccine After Exposure to +45°C for 12 months In-vitro and In-vivo Studies Pave the Way for Fridge-Free Vaccines Stablepharma Ltd and BB-NCIPD Ltd (Bul Bio) formed a strategic partnership in 2021 to produce the world’s first fridge-free Tetanus diphtheria (Td) vaccine, StablevaX™-Td. Encouraging potency and […]

June 15th, 2022 London, UK – Stablepharma Ltd., a UK-based biotechnology company pioneering fridge-free vaccines today announced a collaboration agreement with a world leader in sterile manufacturing and serving science, to manufacture thermostable Tetanus diphtheria (Td) vaccines at their facilities in Italy. “Our new partner is one of the world’s leading sterile manufacturing companies, offering a […]

As the country wound down for the long bank holiday weekend, Professor Jonathan Heeney was juggling a mountain of work in Cambridge. “The thing is, what we’re doing is really timely,” he says. For years, Heeney and his team at biotech company DIOSynVax had been working on creating a vaccine suitable for three infectious viruses […]

Stablepharma Ltd are delighted to that our CEO & Executive Director, Özgür Tuncer has been named as one of London’s most impressive and successful Directors in the Biotechnology space by Best Startup UK . Best Startup UK tracks over 130,000 UK startups and over 500,000 people who hold key positions in these companies. They use […]

In the UK Government strategy ‘Living with COVID’, COVID-19 vaccines represent the first line of defence against SARS-CoV-2. Advances in vaccine technologies allowed manufacturers to develop the first generation of COVID-19 vaccines in record time (see Research from the House of Commons Library and POST on COVID-19 vaccines). Current vaccines are highly effective against hospitalisation […]

Stablepharma has achieved an important milestone with the Td-StablevaX-M™, having successfully demonstrated stability of the reformulated Td vaccine for up to 10 months at +45ºC in collaboration with our strategic partner BB–NCIPD Ltd (Bul Bio). Td-StablevaX-M™ is a pre-filled disposable syringe containing dry stabilised tetanus diptheria vaccine for administration by injection following rehydration. Results demonstrate […]

Anh Go joins the company as Strategy and Operations Manager and brings a wealth of diverse and cross-sector experience from healthcare, life science and government. Prior to joining Stablepharma, Anh was part of the Healthcare and Life Sciences Consulting Practice at KPMG in the UK and Australia, where she focused on managing global patient pathway […]